FDA warned earlier this week that Thermo Fisher Scientific’s TaqPath test could have a risk of false results. This follows the Waltham, MA-based company exiting its bid to acquire Qiagen for $12.5 billion.
https://i1.wp.com/mtgelectronics.com/wp-content/uploads/2020/08/IMG_Aug192020at103453AM.jpg?fit=565%2C292&ssl=1 292 565 admin https://mtgelectronics.com/wp-content/uploads/2020/07/MTG-logo-for-site-300x100-1.png admin2020-08-25 14:04:332020-08-25 15:37:36Thermo Fisher’s COVID-19 Test Could Have Inaccurate Results
- Electrified Vehicles: The Race to Mass AdoptionJanuary 21, 2021 - 5:02 pm
- CRL Announces Strain Sensor for Curved Mounting SurfacesJanuary 20, 2021 - 1:05 pm
- Murata Announced Completion of New Raw Ceramic Manufacturing Plant January 20, 2021 - 10:31 am
- Romanian government approves Naval Strike Missile buy from RaytheonJanuary 16, 2021 - 11:38 am